CN1348442A - 新的磺胺化合物及其应用 - Google Patents

新的磺胺化合物及其应用 Download PDF

Info

Publication number
CN1348442A
CN1348442A CN00806622A CN00806622A CN1348442A CN 1348442 A CN1348442 A CN 1348442A CN 00806622 A CN00806622 A CN 00806622A CN 00806622 A CN00806622 A CN 00806622A CN 1348442 A CN1348442 A CN 1348442A
Authority
CN
China
Prior art keywords
chloro
benzenesulfonamide
dichlorophenyl
methyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00806622A
Other languages
English (en)
Chinese (zh)
Inventor
D·W·史密斯
B·穆诺茨
K·斯里尼瓦桑
C·P·伯格斯特龙
P·V·查图维达拉
M·S·德什潘得
D·J·基维
W·Y·劳
M·F·帕克
C·P·斯洛安
O·B·瓦拉斯
H·H·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConvTec Technologies Inc
Merck and Co Inc
Original Assignee
ConvTec Technologies Inc
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConvTec Technologies Inc, Merck and Co Inc filed Critical ConvTec Technologies Inc
Publication of CN1348442A publication Critical patent/CN1348442A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
    • C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
CN00806622A 1999-02-26 2000-02-22 新的磺胺化合物及其应用 Pending CN1348442A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US12274899P 1999-02-26 1999-02-26
US12274699P 1999-02-26 1999-02-26
US12190699P 1999-02-26 1999-02-26
US60/121,906 1999-02-26
US60/122,748 1999-02-26
US60/122,746 1999-02-26
US13099499P 1999-04-23 1999-04-23
US13099599P 1999-04-23 1999-04-23
US60/130,995 1999-04-23
US60/130,994 1999-04-23

Publications (1)

Publication Number Publication Date
CN1348442A true CN1348442A (zh) 2002-05-08

Family

ID=27537622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00806622A Pending CN1348442A (zh) 1999-02-26 2000-02-22 新的磺胺化合物及其应用

Country Status (18)

Country Link
US (1) US6967196B1 (enExample)
EP (1) EP1159263A1 (enExample)
JP (1) JP2002537376A (enExample)
KR (1) KR20020006626A (enExample)
CN (1) CN1348442A (enExample)
AU (1) AU773273B2 (enExample)
BR (1) BR0008965A (enExample)
CA (1) CA2366919A1 (enExample)
CZ (1) CZ20013000A3 (enExample)
HU (1) HUP0201020A3 (enExample)
IL (1) IL144781A0 (enExample)
MX (1) MXPA01008606A (enExample)
NO (1) NO20014135L (enExample)
NZ (1) NZ514453A (enExample)
PE (1) PE20001542A1 (enExample)
PL (1) PL349781A1 (enExample)
UY (1) UY26042A1 (enExample)
WO (1) WO2000050391A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718689A (zh) * 2007-10-31 2012-10-10 百时美施贵宝公司 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物
CN103193691A (zh) * 2012-01-06 2013-07-10 中国科学院上海药物研究所 磺胺类化合物、药物组合物及其制法和应用
CN104151277A (zh) * 2014-06-30 2014-11-19 北京万全德众医药生物技术有限公司 盐酸决奈达隆一种氧化杂质的制备方法
CN106466313A (zh) * 2015-08-18 2017-03-01 中国科学院上海药物研究所 一类磺酰胺基取代的酰胺类衍生物在制备用于治疗阿尔茨海默病的药物中的用途

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001026506A (ja) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd スルホンアミド誘導体
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US7312358B2 (en) 2000-10-17 2007-12-25 Laboratoires Serono Sa Pharmaceutically active sulfanilide derivatives
SG128491A1 (en) 2000-12-13 2007-01-30 Wyeth Arqule Inc Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
EP1435955A2 (en) * 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
ATE515495T1 (de) 2001-08-03 2011-07-15 Schering Corp Gamma sekretase inhibitoren
WO2003013527A1 (en) * 2001-08-03 2003-02-20 Schering Corporation Sulfonamide derivatives as gamma secretase inhibitors
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
NZ533603A (en) 2001-12-20 2007-02-23 Bristol Myers Squibb Co Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2003055850A1 (en) 2001-12-27 2003-07-10 Daiichi Pharmaceutical Co., Ltd. β-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
DE10201392A1 (de) * 2002-01-16 2003-07-31 Bayer Ag Phenylsulfoxide und-sulfone
RU2321394C2 (ru) * 2002-06-11 2008-04-10 Уайт Замещенные фенилсульфонамидные ингибиторы продуцирования бета-амилоида
US6989399B2 (en) 2002-08-01 2006-01-24 Bristol-Myers Squibb Company Antiamyloid phenylsulfonamides: N-alkanol derivatives
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223040D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
WO2004033418A2 (en) 2002-10-11 2004-04-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2004080952A1 (de) * 2003-03-10 2004-09-23 Bayer Healthcare Ag Phenylsulfonamid-derivate zur behandlung der alzheimerschen krankheit
RU2342374C2 (ru) 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
WO2004092146A2 (en) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
JP2007501859A (ja) 2003-05-13 2007-02-01 シェーリング　コーポレイション γ−セクレターゼ阻害剤としての架橋ｎ−アリールスルホニルピペリジン
JP4818114B2 (ja) 2003-05-16 2011-11-16 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害剤としてのシクロヘキシルスルホン類
CA2529256A1 (en) * 2003-06-23 2004-12-29 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
KR20060066057A (ko) 2003-06-30 2006-06-15 다이이찌 세이야꾸 가부시기가이샤 복소환 메틸 설폰 유도체
TW200524910A (en) 2003-08-08 2005-08-01 Schering Corp Cyclic amine BACE-1 inhibitors having a heterocyclic substituent
TW200519084A (en) 2003-08-08 2005-06-16 Schering Corp Cyclic amine bace-1 inhibitors having a benzamide substituent
GB0323258D0 (en) 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
RU2364587C2 (ru) * 2003-10-29 2009-08-20 Элан Фармасьютикалз, Инк. N-замещенные бензолсульфонамиды
CA2552558A1 (en) 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
CA2559047A1 (en) 2004-03-11 2005-09-29 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
WO2005097751A2 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
KR100966749B1 (ko) 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
AR050994A1 (es) 2004-06-30 2006-12-13 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas, y composicion farmaceutica en base al compuesto
AR049726A1 (es) 2004-07-22 2006-08-30 Schering Corp Amidas sustituidas inhibidoras de beta secretasa
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
CA2585555A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids
EP1838701A1 (en) 2005-01-18 2007-10-03 Elan Pharmaceuticals Inc. N-substituted heterocyclic sulfonamides
CN101146800A (zh) * 2005-01-27 2008-03-19 生物工程大学精神物质实验室 用于治疗阿尔茨海默病的有机化合物，它们的用途和制备方法
RU2404968C2 (ru) * 2005-04-08 2010-11-27 Дайити Санкио Компани, Лимитед Пиридилдиметилсульфоновое производное
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI386207B (zh) 2005-11-24 2013-02-21 Eisai R&D Man Co Ltd 味啉類型之肉桂醯胺化合物
MX2008009414A (es) 2006-01-20 2008-10-01 Schering Corp Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa.
JP2009533016A (ja) * 2006-02-06 2009-09-17 イーラン ファーマスーティカルズ、インコーポレイテッド プレセニリン１特異的阻害剤及びそれらの使用
US8133857B2 (en) * 2006-03-07 2012-03-13 The Brigham and Women's FHospital, Inc. NOTCH inhibition in the treatment of atherosclerosis
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
JP2009533419A (ja) 2006-04-11 2009-09-17 アクテリオン ファーマシューティカルズ リミテッド 新規スルホンアミド化合物
WO2007143422A2 (en) 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
US20110053995A1 (en) * 2006-11-16 2011-03-03 The Regents Of The University Of California Benzenesulfonanilide compound inhibitors of urea transporters
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
CA2691542A1 (en) 2007-07-05 2009-01-15 Schering Corporation Tetrahydropyranochromene gamma secretase inhibitors
CN101970445A (zh) 2007-07-17 2011-02-09 先灵公司 苯磺酰基-色满、硫代色满、四氢萘和相关γ分泌酶抑制剂
EP2181992B8 (en) 2007-08-31 2013-06-26 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
KR101546712B1 (ko) 2007-11-20 2015-08-24 얀센 파마슈티카 엔.브이. 히스타민 ｈ3 수용체의 조절제로서 사이클로알킬옥시- 및 헤테로사이클로알킬옥시피리딘 화합물
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
WO2009120783A1 (en) * 2008-03-25 2009-10-01 The Johns Hopkins University High affinity inhibitors of hepatitis c virus ns3/4a protease
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
TW201020247A (en) * 2008-11-06 2010-06-01 Gruenenthal Gmbh Substituierte disulfonamide
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
JP5746685B2 (ja) 2009-05-14 2015-07-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ロイコトリエンａ４加水分解酵素のモジュレーターとしての縮合二環式ヘテロアリール部分を２つ有する化合物
BR112014021498A2 (pt) * 2012-02-29 2017-07-18 Institute For Hepatitis And Virus Res composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
US9688715B2 (en) 2012-06-22 2017-06-27 Temple University—Of the Commonwealth System of Higher Education Synthetic pGpG analogs, methods of preparation and methods of use
CA2885908A1 (en) * 2012-09-27 2014-04-03 F. Hoffmann-La Roche Ag Substituted sulfonamide compounds
EP2981522A4 (en) 2013-04-05 2016-08-31 Salk Inst For Biological Studi PPAR AGONISTS
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP2932966A1 (en) 2014-04-16 2015-10-21 Novartis AG Gamma secretase inhibitors for treating respiratory diseases
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
CA2969756A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
WO2017062468A1 (en) 2015-10-07 2017-04-13 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
JP6925367B2 (ja) 2016-04-13 2021-08-25 ミトブリッジ，インコーポレーテッド Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
CA3133929A1 (en) 2019-04-19 2020-10-22 Lin Zhi Crystalline forms and methods of producing crystalline forms of a compound
WO2021007474A1 (en) * 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CN112457687B (zh) * 2019-09-06 2022-10-25 台湾永光化学工业股份有限公司 新颖反应性染料
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5703084A (en) * 1996-07-15 1997-12-30 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Adenosine deaminase inhibitors
CZ16899A3 (cs) * 1996-07-22 1999-08-11 Monsanto Company Thiolsulfonamidové inhibitory metaloproteázy
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718689A (zh) * 2007-10-31 2012-10-10 百时美施贵宝公司 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物
CN103193691A (zh) * 2012-01-06 2013-07-10 中国科学院上海药物研究所 磺胺类化合物、药物组合物及其制法和应用
CN103193691B (zh) * 2012-01-06 2017-08-25 中国科学院上海药物研究所 磺胺类化合物、药物组合物及其制法和应用
CN104151277A (zh) * 2014-06-30 2014-11-19 北京万全德众医药生物技术有限公司 盐酸决奈达隆一种氧化杂质的制备方法
CN106466313A (zh) * 2015-08-18 2017-03-01 中国科学院上海药物研究所 一类磺酰胺基取代的酰胺类衍生物在制备用于治疗阿尔茨海默病的药物中的用途

Also Published As

Publication number Publication date
NZ514453A (en) 2003-04-29
BR0008965A (pt) 2002-02-26
AU3241000A (en) 2000-09-14
NO20014135L (no) 2001-09-27
HUP0201020A2 (hu) 2002-07-29
MXPA01008606A (es) 2003-05-05
KR20020006626A (ko) 2002-01-23
PL349781A1 (en) 2002-09-09
HUP0201020A3 (en) 2003-04-28
JP2002537376A (ja) 2002-11-05
EP1159263A1 (en) 2001-12-05
US6967196B1 (en) 2005-11-22
CZ20013000A3 (cs) 2002-02-13
CA2366919A1 (en) 2000-08-31
AU773273B2 (en) 2004-05-20
UY26042A1 (es) 2000-10-31
PE20001542A1 (es) 2001-01-08
NO20014135D0 (no) 2001-08-24
WO2000050391A1 (en) 2000-08-31
IL144781A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
CN1348442A (zh) 新的磺胺化合物及其应用
CN1161331C (zh) 肼衍生物
CN1289469C (zh) α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
CN1213040C (zh) 丝氨酸蛋白酶抑制剂
CN1225463C (zh) 具有钾通道阻断作用的芳基化呋喃和噻吩甲酰胺
CN1192018C (zh) 抑制细胞附着的抗炎和免疫抑制的化合物
CN1291184A (zh) 环烯衍生物、其制造方法和用途
CN1732161A (zh) 1,3－二氨基－2－羟基丙烷前体药物衍生物
CN1551866A (zh) 羧酸衍生物化合物及包含这些化合物为活性成分的药物
CN1299344A (zh) 新颖的脲衍生物
CN1638757A (zh) 组织蛋白酶半胱氨酸蛋白酶抑制剂
CN1946703A (zh) 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂
CN1703397A (zh) 磺酰基氨基－乙酸衍生物及其作为阿立新受体拮抗剂的应用
CN1585746A (zh) β－淀粉样蛋白产生和分泌的抑制剂
CN1503790A (zh) β淀粉样蛋白产生的杂环磺酰胺类抑制剂
CN1310709A (zh) N,n－取代环胺衍生物
CN1438991A (zh) 作为中性内肽酶的抑制剂的环戊基－取代的戊二酰胺衍生物
CN1353691A (zh) 抑制细胞附着的抗炎和免疫抑制的化合物
CN1703221A (zh) 作为黑皮质素受体配体用于治疗肥胖症的2－烷基－(2－氨基－3－芳基－丙酰基)哌嗪衍生物及相关化合物
CN1761657A (zh) Ep4受体拮抗剂
CN101031555A (zh) 具有vap－1抑制活性的噻唑衍生物
CN1148346C (zh) 肼衍生物
CN1269801C (zh) 氨基酸衍生物以及含有该衍生物作为有效成分的药剂
CN1360577A (zh) 作为基质金属蛋白酶抑制剂的异羟肟酸衍生物
CN1040366A (zh) 丁烯酸或丙烯酸衍生物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication